Affiliation:
1. Sciarc Institute, Baierbrunn, Germany
2. Forschergruppe Diabetes e.V., Munich-Neuherberg, Germany
Abstract
In recent years, continuous intraperitoneal insulin infusion (CIPII) has become a favored treatment alternative for patients with subcutaneous insulin resistance, mainly due to its ability of mimicking physiological conditions of insulin absorption. CIPII has been shown to improve glycemic control as well as to reduce hypoglycemic events and to lead to increased patient satisfaction and quality of life (QoL). Among CIPII delivery systems, Diaport stands out due to its low side effects, its demonstrated clinical efficacy and the potential for integration into closed-loop systems.
Subject
Biomedical Engineering,Bioengineering,Endocrinology, Diabetes and Metabolism,Internal Medicine
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献